Biodexa Pharmaceuticals (BDRX) Interest Expenses (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Interest Expenses of -$180096.2 for Q2 2025, down 186.36% sequentially from -$62891.6 in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Interest Expenses (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Interest Expenses for 12 years, with the latest figure at -$180096.2 in Q2 2025.
- Quarterly Interest Expenses changed N/A year-over-year to -$180096.2 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$242987.8 (down 168.73% YoY) and the FY2025 annual result came in at -$301938.9, down 242.57% from the prior year.
- Interest Expenses declined to -$180096.2 in Q2 2025 per BDRX's latest filing, from -$62891.6 in the prior quarter.
- Over five years, Interest Expenses peaked at -$27530.0 in Q2 2023 and troughed at -$216759.6 in Q3 2021.
- A 5-year average of -$107914.1 and a median of -$62891.6 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2022: Interest Expenses slumped 682.41% in 2021, then jumped 86.61% in 2022.
- Over 5 years, Interest Expenses stood at -$210289.7 in 2021, then surged by 86.61% to -$28150.3 in 2022, then climbed by 2.2% to -$27530.0 in 2023, then sank by 128.45% to -$62891.6 in 2024, then tumbled by 186.36% to -$180096.2 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered -$180096.2, -$62891.6, and -$27530.0 for Q2 2025, Q4 2024, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -304,608.06 |
| Dec 31, 2025 | -304,608.06 |
| Jun 30, 2025 | -180,096.17 |
| Jun 30, 2025 | -180,096.17 |
| Dec 31, 2024 | -62,891.59 |
| Dec 31, 2024 | -62,891.59 |
| Jun 30, 2023 | -27,529.99 |
| Jun 30, 2023 | -27,529.99 |
| Dec 31, 2022 | -28,150.28 |
| Dec 31, 2022 | -28,150.28 |
| Sep 14, 2022 | -29,681.42 |
| Sep 14, 2022 | -29,681.42 |
| Dec 31, 2021 | -210,289.65 |
| Dec 31, 2021 | -210,289.65 |
| Sep 17, 2021 | -216,759.65 |
| Sep 17, 2021 | -216,759.65 |
| Dec 31, 2020 | -569,114.38 |
| Dec 31, 2020 | -569,114.38 |
| Sep 10, 2020 | -27,704.17 |
| Sep 10, 2020 | -27,704.17 |